Cite
HARVARD Citation
Pietrantonio, F. et al. (n.d.). O-025A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients. Annals of oncology. p. . [Online].